Biotechnology

Palatin Tech

Palatin Tech released FY2026 Q1 earnings on November 14 During-Market EST, actual revenue USD 8.848 M, actual EPS USD 4.2599

Palatin reports Q1 2026 financial results and completes public offering

Palatin Tech released FY2025 Annual Earnings on September 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -32.1489 (forecast USD -49.5)

Palatin Tech released FY2025 Q4 earnings on September 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.7236 (forecast USD -9.5)

Palatin Technologies Announces Positive Preclinical Results for PL7737

Palatin Technologies Inc. amends its charter to issue new shares

Palatin Technologies Reports Q3 2025 Earnings, Net Loss Decreases

Palatin Tech released FY2025 9 Months Earnings on May 14 (EST), Actual Revenue: USD 0, Actual EPS: USD -34.7618

Palatin Tech released FY2025 Q3 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.1317 (forecast USD -8.5)

Palatin Technologies to Update on Obesity and Ophthalmology Project Progress

Palatin Technologies Inc. Reports Q1 2025 Net Loss of $4.8 Million

Director Robert K. DeVell Jr. Acquires Shares in Palatin Technologies

Palatin Technology Presents Phase III Data for Dry Eye Treatment PL9643

Palatin Technologies Announces Public Offering Pricing Expected to Raise $23 Million

Palatin Announces Promising Preclinical Data for GLAUCOMA Therapy PL9588

Palatin Appeals Delisting Notice

Palatin Technologies Presents Positive Phase 2b Data on Diabetic Nephropathy at National Kidney Foundation Spring Meeting

Palatin Technologies Submits Application to Issue Up to 17.3 Million Shares of Common Stock

Palatin Technologies Inc. Announces Successful Phase 2 Obesity Study for BMT-801

Palatin Technologies announces positive results for PL8177 study on ulcerative colitis

Foxx Development

Mobile-Health Network Solutions

Nuvve

Datavault AI

Iveda Solutions

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

CCSC Tech

BOLD EAGLE ACQUISITION CORP COM USD0.0001 (SUB/RIGHTS)

Harrison Global

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

CureVac BV

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap